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SUMMARY. Non-irritant, non-comedogenic and non-polar emollients were pre-selected for determina-
tions of relative dielectric permittivity and solubility of benzoyl peroxide (BP). Those solvents capable of
solubilizing BP in concentrations commonly utilised in topical formulations (between 1 and 10 %) were
taken into account for stability studies. The developed pre-formulations were also studied for acute irrita-
tion both clinically and instrumentally. Even though the solubility of BP in the solvents studied had rela-
tively low values; in some cases, such as with caprylic/capric triglyceride (CapCap) and dicaprylyl carbon-
ate (DicCar) it has been possible to obtain acceptable concentrations of BP from a therapeutic viewpoint
(19.9 and 19.5 mg/mL, respectively). Two BP pre-formulations (PBCapCap and PBDicCar) with enhanced
stability and with the capability to decrease adverse application site reaction by maintaining moisture in
the stratum corneum were developed with potential application in topical formulations of BP with solvents
of low relative dielectric permittivity (CapCap and DicCar, respectively). 
